RACCFinancial Services · Shell Companies

RACC Stock Forecast: Research Alliance Corp. III Price Predictions for 2026-2027

Last close, 3 Aug 2026

$22

+2.99% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 5 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap

$226.7M

Ticker Nerd rank

5 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

+68.7%

+98.2%

From high

0.0%

From low

+117.9%

$10

$22

Range since 20 May 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

RACC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Research Alliance Corp. III on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

5 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Volatility

Quality

Value

Revisions

Momentum

Growth

Accruals

Issuance

Size (68): Smaller than most of the companies we track.

Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Research Alliance Corp. III — and when they’d sell — is the membership.

Wall Street

RACC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RACC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 20 May 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

RACC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Research Alliance Corp. III (RACC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: —
Price / book: −4916.7×
EV / EBITDA: —

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: —
Return on assets: —
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RACC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelShell Companies

Company	Market cap	TKN rank
RACCResearch Alliance Corp. III	$226.7M	5
TVIVTexas Ventures Acquisition IV Corp.	$198.0M	6
ETSSEnergy Transition Special Opportunities	$197.6M	6
LTGRLong Table Growth Corp.	$197.6M	6
LKSPLake Superior Acquisition Corp.	$198.6M	27
FIGXFIGX Capital Acquisition Corp.	$199.0M	32
AIIAAI Infrastructure Acquisition Corp.	$196.8M	18

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RACC appears on the weeks it earns a place.

News

Latest RACC news & analysis

Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome

GlobeNewsWire · 27 July 2026positive

Research Alliance Corporation III (RACC) announced a definitive business combination agreement with Oak Hill Bio to create a publicly listed rare disease biotechnology company focused on advancing rugonersen for Angelman syndrome.

Why it matters — This provides RACC with a merger target — Oak Hill Bio — and the deal is expected to fund development of rugonersen through Phase 3 readout and potential NDA submission in the second half of 2029.

FAQ

Frequently asked questions about RACC stock

How does Ticker Nerd's model rank RACC?

As at 1 Aug 2026, Research Alliance Corp. III ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (68 of 100).

What is the RACC stock forecast for 2030?

No analyst covering Research Alliance Corp. III publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RACC are extrapolating price history, which says nothing about the business.

What does Research Alliance Corp. III do?

What is the latest news on RACC?

The most recent item we track (GlobeNewsWire, 27 July 2026): "Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome". Research Alliance Corporation III (RACC) announced a definitive business combination agreement with Oak Hill Bio to create a publicly listed rare disease biotechnology company focused on advancing rugonersen for Angelman syndrome.

Company

About Research Alliance Corp. III.

Research Alliance Corporation III is a special purpose acquisition company formed in 2026 and headquartered in New York, New York. The company operates as a blank check entity, established to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more operating businesses. Research Alliance Corporation III primarily targets opportunities in healthcare and healthcare-related industries, with a particular emphasis on drug development, health technology, diagnostics, and healthcare services. Its structure allows institutional and individual investors to gain exposure to a private operating company that may ultimately combine with the SPAC. The sponsor and management team draw on experience in life sciences investing and analysis to identify and evaluate potential targets. In the broader financial market, Research Alliance Corporation III serves as an intermediary vehicle, channeling capital from public investors to privately held healthcare and health-tech companies seeking access to public markets and additional funding via a business combination transaction.

CEO Dr. Matthew D. Hammond M.B.A., Ph.D. · United States